Aprea Therapeutics Inc. Company Profile
NASDAQ: APREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aprea Therapeutics at a glance
Aprea Therapeutics Inc. (NASDAQ: APRE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Doylestown, PA. Aprea Therapeutics is led by Dr. Oren Gilad Ph.D. and employs about 8 people. The company's shares have traded publicly since 2019.
At a market capitalization of $7.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001781983, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Aprea Therapeutics Inc.
- Ticker
- NASDAQ: APRE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Oren Gilad Ph.D.
- Employees
- 8
- Headquarters
- 3805 Old Easton Road, Doylestown, PA, United States
- Phone
- 215 948 4119
- Website
- aprea.com
- IPO year
- 2019
- Market cap
- $7.61M
- SEC CIK
- 0001781983
Companies similar to Aprea Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US Inc. | 5.02 | -8.89% | $7.58M | vs APRE |
| SKYESkye Bioscience Inc. | 1.69 | +0.60% | $7.48M | vs APRE |
| INMInMed Pharmaceuticals Inc. | 1.36 | +2.26% | $7.47M | vs APRE |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | 0.00% | $7.82M | vs APRE |
| FBLGFibroBiologics Inc. | 1.13 | +1.80% | $7.86M | vs APRE |
| AZTRAzitra Inc | 0.1299 | -1.59% | $7.87M | vs APRE |
| LGVNLongeveron Inc. Class A | 2.48 | +4.64% | $7.91M | vs APRE |
| SNGXSoligenix Inc. | 0.3636 | +4.90% | $7.91M | vs APRE |